Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Pharma Industry Analysis

UpdatedApr 23, 2026
DataAggregated Company Financials
Companies15
  • 7D-1.9%
  • 3M6.9%
  • 1Y34.4%
  • YTD6.8%

Over the last 7 days, the Pharma industry has dropped 1.9%, driven by a pullback from AstraZeneca of 1.6%. Meanwhile, Animalcare Group actually outperformed within the industry, gaining 35% in the last week. In the past year, the industry has gained 34%. Earnings are forecast to grow by 10% annually.

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 23 Apr 2026UK£344.9bUK£90.3bUK£15.5b18.5x22.2x3.8x
Sat, 21 Mar 2026UK£331.9bUK£90.8bUK£15.7b21.4x21.2x3.7x
Mon, 16 Feb 2026UK£363.5bUK£89.7bUK£15.3b24.1x23.7x4.1x
Wed, 14 Jan 2026UK£329.7bUK£89.5bUK£14.6b21.2x22.6x3.7x
Fri, 12 Dec 2025UK£321.6bUK£89.5bUK£14.6b21.2x22x3.6x
Sun, 09 Nov 2025UK£309.2bUK£90.4bUK£14.8b21.1x20.9x3.4x
Tue, 07 Oct 2025UK£298.0bUK£87.6bUK£11.7b19.1x25.5x3.4x
Thu, 04 Sep 2025UK£287.8bUK£87.7bUK£11.7b21.9x24.5x3.3x
Sat, 02 Aug 2025UK£268.3bUK£88.3bUK£11.5b28.5x23.4x3x
Mon, 30 Jun 2025UK£256.1bUK£85.8bUK£10.5b25.8x24.3x3x
Wed, 28 May 2025UK£265.3bUK£86.4bUK£10.6b27x25x3.1x
Fri, 25 Apr 2025UK£259.3bUK£86.3bUK£9.6b27.1x27.1x3x
Sun, 23 Mar 2025UK£284.4bUK£87.8bUK£9.7b32.7x29.4x3.2x
Tue, 18 Feb 2025UK£283.2bUK£88.8bUK£9.5b31x30x3.2x
Thu, 16 Jan 2025UK£226.8bUK£76.6bUK£7.9b31x28.6x3x
Sat, 14 Dec 2024UK£223.9bUK£75.1bUK£7.8b31.5x28.9x3x
Mon, 11 Nov 2024UK£217.2bUK£72.6bUK£7.6b30.7x28.6x3x
Wed, 09 Oct 2024UK£248.0bUK£72.1bUK£9.0b31.1x27.5x3.4x
Fri, 06 Sep 2024UK£268.9bUK£71.9bUK£9.0b39.8x30x3.7x
Sun, 04 Aug 2024UK£266.8bUK£72.9bUK£9.0b38.9x29.6x3.7x
Tue, 02 Jul 2024UK£260.5bUK£71.7bUK£9.6b29.8x27.2x3.6x
Thu, 30 May 2024UK£263.9bUK£71.5bUK£9.6b31.8x27.6x3.7x
Sat, 27 Apr 2024UK£261.0bUK£71.8bUK£10.1b30.7x26x3.6x
Mon, 25 Mar 2024UK£240.9bUK£70.9bUK£9.8b31.3x24.7x3.4x
Wed, 21 Feb 2024UK£233.4bUK£69.7bUK£9.6b35.7x24.3x3.3x
Fri, 19 Jan 2024UK£236.6bUK£68.9bUK£10.7b35.9x22.2x3.4x
Sun, 17 Dec 2023UK£227.4bUK£69.0bUK£10.7b33.9x21.3x3.3x
Tue, 14 Nov 2023UK£227.5bUK£70.3bUK£10.8b53.3x21x3.2x
Thu, 12 Oct 2023UK£245.7bUK£70.2bUK£10.4b73.9x23.7x3.5x
Sat, 09 Sep 2023UK£241.0bUK£69.7bUK£10.3b53.5x23.5x3.5x
Mon, 07 Aug 2023UK£238.4bUK£68.9bUK£10.2b52.8x23.5x3.5x
Wed, 05 Jul 2023UK£233.5bUK£67.7bUK£7.9b55.1x29.7x3.4x
Fri, 02 Jun 2023UK£248.1bUK£68.3bUK£7.9b55.5x31.2x3.6x
Sun, 30 Apr 2023UK£254.1bUK£68.2bUK£7.9b55.7x32x3.7x
Price to Earnings Ratio

32x


Total Market Cap: UK£254.1bTotal Earnings: UK£7.9bTotal Revenue: UK£68.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Pharma Industry Price to Earnings3Y Average 25.8x202420252026
Current Industry PE
  • Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 22.2x which is lower than its 3-year average PE of 25.8x.
  • The 3-year average PS ratio of 3.4x is lower than the industry's current PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 9.8% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market-0.41%
Healthcare-1.86%
Pharma-1.86%
Pharma-1.86%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ANCR Animalcare GroupUK£3.3334.6%
+UK£59.0m		44.6%PE77x
FUM Futura MedicalUK£0.01526.2%
+UK£1.8m		-84.6%PS1.1x
SAR Sareum HoldingsUK£0.212.4%
+UK£690.3k		34.4%PB24.9x
INC IncantheraUK£0.01325.0%
+UK£344.8k		-79.2%PS287.4x
NFX NuformixUK£0.00185.9%
+UK£261.0k		53.2%PB6.2x

Latest News

HIK
UK£13.22
Hikma Pharmaceuticals
7D
-1.9%
1Y
-30.6%
AZN
UK£145.36
AstraZeneca
7D
-1.6%
1Y
40.3%
HLN
UK£3.46
Haleon
7D
-2.0%
1Y
-9.1%

HLN: Cash Returns And China Expansion Will Support Future Re Rating Potential

Narrative Update on Haleon Haleon's analyst price targets have shifted modestly higher, with recent moves such as Berenberg's adjustment to £5.12 from £5.10 and Morgan Stanley's move to £4.40 from £4.20, as analysts point to slightly stronger assumptions for revenue growth and profit margins, along with a marginally lower future P/E. Analyst Commentary Recent research points to a generally constructive tone around Haleon, with several bullish analysts adjusting price targets higher in the latest updates.
GSK
UK£20.75
GSK
7D
-2.6%
1Y
50.5%
FUM
UK£0.015
Futura Medical
7D
26.2%
1Y
-84.6%
ANCR
UK£3.33
Animalcare Group
7D
34.6%
1Y
44.6%
STX
UK£0.092
Shield Therapeutics
7D
-1.1%
1Y
293.6%

STX: Expanded Pediatric Reach And China Entry Will Support Stronger Future Earnings

Analysts have trimmed their fair value estimate for Shield Therapeutics to £0.14 per share, citing updated assumptions that combine a lower revenue growth outlook with a higher projected profit margin and a reduced future P/E multiple. What's in the News EMA's Committee for Medicinal Products for Human Use issued a positive opinion to extend FeRACCRU's indication to include adolescents, so it is now indicated for iron deficiency in adults and pediatric patients 12 years and older in Europe, with all measures in the agreed Pediatric Investigation Plan confirmed as fulfilled (Key Developments).
HCM
UK£2.10
HUTCHMED (China)
7D
-4.5%
1Y
-9.5%

HCM: Late Stage Oncology Trials And Guidance Will Drive Future Reassessment

Analysts have adjusted their price target on HUTCHMED (China) slightly, linking the change to updated assumptions for revenue growth and profit margins, together with a higher future P/E of 58.40x. What's in the News HUTCHMED issued 2026 guidance for Oncology/Immunology consolidated revenue in a range of US$330m to US$450m, providing a management view of expected business activity for the year (corporate guidance).
EAH
UK£0.94
ECO Animal Health Group
7D
-9.7%
1Y
74.8%
IMM
UK£0.044
ImmuPharma
7D
-9.4%
1Y
69.2%
NFX
UK£0.0018
Nuformix
7D
5.9%
1Y
53.2%
SAR
UK£0.21
Sareum Holdings
7D
2.4%
1Y
34.4%
INC
UK£0.013
Incanthera
7D
25.0%
1Y
-79.2%